Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
PuraPharm Corp. Ltd. ( (HK:1498) ) has issued an announcement.
PuraPharm Corporation Limited announced that during their extraordinary general meeting held on October 24, 2025, shareholders approved two key resolutions. These resolutions included the ratification of a Patent Licence Agreement and the issuance of Consideration Shares to satisfy a HK$40,200,000 licence fee. The unanimous approval of these resolutions is expected to enhance the company’s operational capabilities and strengthen its market position.
The most recent analyst rating on (HK:1498) stock is a Hold with a HK$0.50 price target. To see the full list of analyst forecasts on PuraPharm Corp. Ltd. stock, see the HK:1498 Stock Forecast page.
More about PuraPharm Corp. Ltd.
PuraPharm Corporation Limited is a company incorporated in the Cayman Islands, primarily involved in the pharmaceutical industry. It focuses on the development and distribution of herbal medicines and related products.
Average Trading Volume: 206,500
Technical Sentiment Signal: Sell
Current Market Cap: HK$167.8M
For an in-depth examination of 1498 stock, go to TipRanks’ Overview page.